103 related articles for article (PubMed ID: 2964898)
1. Potentiation of the gonadotoxicity of Cytoxan in the dog by adjuvant treatment with a luteinizing hormone-releasing hormone agonist.
Goodpasture JC; Bergstrom K; Vickery BH
Cancer Res; 1988 Apr; 48(8):2174-8. PubMed ID: 2964898
[TBL] [Abstract][Full Text] [Related]
2. Effects of medroxyprogesterone acetate or gonadotrophin-releasing hormone agonist on suppression of spermatogenesis in the dog (Canis familiaris).
Paramo RM; Renton JP; Ferguson JM; Concannon PW
J Reprod Fertil Suppl; 1993; 47():387-97. PubMed ID: 8229954
[TBL] [Abstract][Full Text] [Related]
3. Effects of an LHRH agonist analog upon sexual function in male dogs. Suppression, reversibility, and effect of testosterone replacement.
Vickery BH; McRae GI; Briones W; Worden A; Seidenberg R; Schanbacher BD; Falvo R
J Androl; 1984; 5(1):28-42. PubMed ID: 6231277
[TBL] [Abstract][Full Text] [Related]
4. Recrudescence of spermatogenesis in the dog following downregulation using a slow release GnRH agonist implant.
Goericke-Pesch S; Spang A; Schulz M; Ozalp G; Bergmann M; Ludwig C; Hoffmann B
Reprod Domest Anim; 2009 Jul; 44 Suppl 2():302-8. PubMed ID: 19754591
[TBL] [Abstract][Full Text] [Related]
5. Influence of simultaneous gonadotropin-releasing hormone agonist and testosterone treatment on spermatogenesis and potential fertilizing capacity in male monkeys.
Mann DR; Gould KG; Smith MM; Duffey T; Collins DC
J Clin Endocrinol Metab; 1987 Dec; 65(6):1215-24. PubMed ID: 3316265
[TBL] [Abstract][Full Text] [Related]
6. Partial prevention of procarbazine induced germinal cell aplasia in rats by sequential GnRH antagonist and testosterone administration.
Pogach LM; Lee Y; Gould S; Giglio W; Huang HF
Cancer Res; 1988 Aug; 48(15):4354-60. PubMed ID: 3134124
[TBL] [Abstract][Full Text] [Related]
7. Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin as a removable implant "Gonazon"; a preclinical trial.
Ludwig C; Desmoulins PO; Driancourt MA; Goericke-Pesch S; Hoffmann B
Theriogenology; 2009 Apr; 71(7):1037-45. PubMed ID: 19233456
[TBL] [Abstract][Full Text] [Related]
8. Absence of testicular protection by a gonadotropin-releasing hormone analogue against cyclophosphamide-induced testicular cytotoxicity in the mouse.
da Cunha MF; Meistrich ML; Nader S
Cancer Res; 1987 Feb; 47(4):1093-7. PubMed ID: 3542201
[TBL] [Abstract][Full Text] [Related]
9. Inability of continuous long-term administration of D-Nal(2)6-LHRH to abolish fertility in male rats.
Vickery BH; McRae GI; Bergstrom K; Briones W; Worden A; Seidenberg R
J Androl; 1983; 4(4):283-91. PubMed ID: 6225758
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide treatment causes impairment of sperm and its fertilizing ability in mice.
Elangovan N; Chiou TJ; Tzeng WF; Chu ST
Toxicology; 2006 May; 222(1-2):60-70. PubMed ID: 16517039
[TBL] [Abstract][Full Text] [Related]
11. Testosterone suppression of the HPT axis.
MacIndoe JH; Perry PJ; Yates WR; Holman TL; Ellingrod VL; Scott SD
J Investig Med; 1997 Oct; 45(8):441-7. PubMed ID: 9394096
[TBL] [Abstract][Full Text] [Related]
12. D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons.
Lewis RW; Dowling KJ; Schally AV
Proc Natl Acad Sci U S A; 1985 May; 82(9):2975-9. PubMed ID: 3157995
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin releasing hormone (GnRH) agonists in male contraception.
Swerdloff RS; Steiner BS; Bhasin S
Med Biol; 1986; 63(5-6):218-24. PubMed ID: 2939304
[TBL] [Abstract][Full Text] [Related]
14. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.
Peters CA; Walsh PC
N Engl J Med; 1987 Sep; 317(10):599-604. PubMed ID: 2441256
[TBL] [Abstract][Full Text] [Related]
15. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
Doelle G; Linde R; Alexander N; Kirchner F; Vale W; Rivier J; Rabin D
Int J Fertil; 1982; 27(4):234-7. PubMed ID: 6131043
[TBL] [Abstract][Full Text] [Related]
16. Dose-response studies on male reproductive parameters in dogs with nafarelin acetate, a potent LHRH agonist.
Vickery BH; McRae GI; Briones WV; Roberts BB; Worden AC; Schanbacher BD; Falvo RE
J Androl; 1985; 6(1):53-60. PubMed ID: 3156111
[TBL] [Abstract][Full Text] [Related]
17. Development of semen quality following reversible downregulation of testicular function in male dogs with a GnRH agonist implant.
Goericke-Pesch S; Ludwig C; Hoffmann B
Reprod Domest Anim; 2012 Aug; 47(4):625-8. PubMed ID: 22050326
[TBL] [Abstract][Full Text] [Related]
18. Suppression of spermatogenesis by low-level glycerol treatment.
Igdoura SA; Wiebe JP
J Androl; 1994; 15(3):234-43. PubMed ID: 7928665
[TBL] [Abstract][Full Text] [Related]
19. Protection of cyclophosphamide-induced toxicity in reproductive tract histology, sperm characteristics, and DNA damage by an herbal source; evidence for role of free-radical toxic stress.
Rezvanfar M; Sadrkhanlou R; Ahmadi A; Shojaei-Sadee H; Rezvanfar M; Mohammadirad A; Salehnia A; Abdollahi M
Hum Exp Toxicol; 2008 Dec; 27(12):901-10. PubMed ID: 19273545
[TBL] [Abstract][Full Text] [Related]
20. Hypoprolactinemia does not prevent restoration of normal spermatogenesis in gonadotropin-suppressed, testosterone-replaced rats.
Awoniji CA; Roberts D; Chandrashekar V; Hurst BS; Tucker KE; Schlaff WD
J Androl; 1996; 17(1):35-40. PubMed ID: 8833739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
